OMER
Omeros CorporationNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$829.42M
P/E Ratio
10.05
EPS
$1.14
Beta
2.66
52W High
$17.65
52W Low
$2.95
50-Day MA
$12.45
200-Day MA
$9.57
Dividend Yield
—
Profit Margin
871.00%
Forward P/E
62.89
PEG Ratio
0.81
About Omeros Corporation
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
Fundamentals
| Revenue (TTM) | $9.89M |
| Gross Profit (TTM) | $-18.84M |
| EBITDA | $-104.33M |
| Operating Margin | -176.10% |
| Return on Equity | -576.00% |
| Return on Assets | -25.20% |
| Revenue/Share (TTM) | $0.15 |
| Book Value | $-1.69 |
| Price-to-Book | 8.44 |
| Price-to-Sales (TTM) | 83.84 |
| EV/Revenue | 88.86 |
| EV/EBITDA | -1.49 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 14.90% |
| Shares Outstanding | $72.38M |
| Float | $69.80M |
| % Insiders | 3.56% |
| % Institutions | 44.41% |
Historical Volatility
HV 10-Day
68.87%
HV 20-Day
63.04%
HV 30-Day
58.93%
HV 60-Day
63.06%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($33.50 target)
2
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026